Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Sep;10(9):1028-33.e2.
doi: 10.1016/j.cgh.2012.05.008. Epub 2012 May 18.

Prevalence and indicators of portal hypertension in patients with nonalcoholic fatty liver disease

Flavia D Mendes  1 , Ayako Suzuki, Schuyler O Sanderson, Keith D Lindor, Paul Angulo
Affiliations

Prevalence and indicators of portal hypertension in patients with nonalcoholic fatty liver disease

Flavia D Mendes et al. Clin Gastroenterol Hepatol. 2012 Sep.

Abstract

Background & aims: Little is known about the prevalence and severity of portal hypertension in patients with nonalcoholic fatty liver disease (NAFLD). We investigated the prevalence and noninvasive predictors of portal hypertension in patients with NAFLD.

Methods: Signs of portal hypertension, including esophageal varices, splenomegaly, portosystemic encephalopathy, and ascites, were investigated in 354 patients with NAFLD.

Results: One hundred patients had portal hypertension at the time of NAFLD diagnosis (28.2%), 88 of these patients had septal fibrosis or cirrhosis (88%). Fibrosis stage correlated with presence (r = 0.41, P < .0001) and number of findings (r = 0.48, P = .006) of portal hypertension. Of the 204 patients with no or mild fibrosis (stages, 0-2), 12 patients had portal hypertension (6%); they had a significantly higher grade of steatosis, based on biopsy analysis, compared with the 192 patients without portal hypertension (94%). Thrombocytopenia, hyperbilirubinemia, cirrhosis, and obesity were associated independently with portal hypertension. Esophageal varices were found in 57 of the 128 patients undergoing endoscopic screening (44.5%) and were associated independently with thrombocytopenia, type 2 diabetes, and splenomegaly.

Conclusions: Signs of portal hypertension were present in 25% of patients at the time of diagnosis of NAFLD; most had advanced fibrosis or cirrhosis. Portal hypertension can occur in a small proportion of patients with mild or no fibrosis and is associated with the extent of steatosis. Features of advanced liver disease and insulin resistance might identify patients with NAFLD and portal hypertension, and those expected to derive the most benefit from endoscopic screening for esophageal varices.

PubMed Disclaimer

Conflict of interest statement

Disclosures: None of the authors have any conflicts or financial arrangements to disclose related to this study.

Figures

Figure 1
Figure 1
Correlation of findings of portal hypertension and fibrosis stage in 354 patients with NAFLD. Bars represent mean values, and error bars represent standard errors.
Figure 2
Figure 2
Receiver operating characteristic (ROC) curves (A) to predict portal hypertension including fibrosis stage in the model (AUC = 0.93); (B) to predict portal hypertension excluding fibrosis stage from the model (AUC = 0.91); and (C) to predict presence of esophageal varices (AUC = 0.94).
See this image and copyright information in PMC

References

    1. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274–285. - PubMed
    1. Kleiner DE, Brunt EM. Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research. Semin Liver Dis. 2012;32:3–13. - PubMed
    1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346(16):1221–31. - PubMed
    1. Adams LA, Sanderson SO, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol. 2005;42:132–8. - PubMed
    1. Caldwell SH, Oelsner DH, Iezzoni JC, et al. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology. 1999;29:664–9. - PubMed

Publication types

MeSH terms